Patel-Dunn Anisha
Known title: Chief Medical OfficerCIK: 0001864311
Associated companies
Transaction History
| LFST | ▼ Sell | Open Market | 2,602 | $24K | 6/28/2023 | View on chart |
| LFST | ▼ Sell | Open Market | 7,319 | $56K | 4/4/2023 | View on chart |
| LFST | ▲ Buy | Grant | 192,307 | $0 | 3/6/2023 | View on chart |
| LFST | ▼ Sell | Open Market | 3,463 | $18K | 6/13/2022 | View on chart |
| LFST | ▲ Buy | Grant | 76,446 | $0 | 4/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Keybanc Raises LifeStance Health Price Target to $15
Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.
Keybanc Raises LifeStance Health Price Target to $15. Keybanc maintained an Overweight rating on LifeStance Health and raised its price target to $15. This follows the company's recent Q2 2026 earnings call. The stock is currently trading near the middle of its 52-week range, with an average analyst target of $14.40.